Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Rapamycin Press LLC dba Impact Journals is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack... This malicious action will be reported to the FBI.

Corrections:

Correction: Inhibition of fibroblast secreted QSOX1 perturbs extracellular matrix in the tumor microenvironment and decreases tumor growth and metastasis in murine cancer models

PDF | How to cite

Tal Feldman¹, Iris Grossman-Haham¹, Yoav Elkis², Patrick Vilela¹, Neta Moskovits³, Iris Barshack⁴, Tomer M. Salame⁵, Deborah Fass¹ and Tal Ilani¹

¹ Department of Structural Biology, Weizmann Institute of Science, Rehovot 7610001, Israel
² Almog Diagnostic, Shoham 6081513, Israel
³ Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
⁴ Institute of Pathology, Sheba Medical Center Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
⁵ Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot 7610001, Israel

Published: October 06, 2020

This article has been corrected: The funding information has been updated. The correct listing is given below:

This work was supported by the European Research Council [grants number 310649 and 825076]

Original article: Oncotarget. 2020; 11:386–398. DOI: https://doi.org/10.18632/oncotarget.27438.

Publication Alerts

Oncoscience

Post-Publication Promotion

Corrections:

Correction: Inhibition of fibroblast secreted QSOX1 perturbs extracellular matrix in the tumor microenvironment and decreases tumor growth and metastasis in murine cancer models